How it works:
Lapatinib is a dual tyrosine kinase inhibitor that blocks HER2 and EGFR receptors involved in tumour cell growth and survival. It is particularly effective in HER2-positive breast cancer that has spread or progressed despite previous treatment.
Recommended for:
Patients with HER2-positive metastatic breast cancer
When disease progresses after trastuzumab therapy
In combination with capecitabine or hormone therapy, as prescribed
HER2-positive metastatic breast cancer
Progression following previous targeted therapy
HERDUO is taken orally on an empty stomach as prescribed. The dosage and duration are determined by the oncologist based on clinical condition and treatment regimen.
Contraindications:
Hypersensitivity to Lapatinib
Severe liver dysfunction
Pregnancy and breastfeeding
Under 18 years of age
Serious cardiac conditions
Side effects:
Diarrhoea, nausea, vomiting
Skin rash and reactions
Elevated liver enzymes
Fatigue, headache
Rare cardiac events
